Management Team

Diana Thomas, M.A.

Founder & CEO

In 1985 Diana Thomas graduated Magna Cum Laude from Arizona State University with a Master’s Degree in Architectural History. Her undergraduate work was completed in Canada, where she has dual citizenship. From 1979 to 1996 Ms. Thomas held several leadership positions in the study and preservation of historic architecture in both the United States and Canada. She was head of Alberta’s Provincial Inventory of Historic Sites, where she gained more than seven years of managerial experience, initiated innovations in her field, obtained private funding, and implemented new database systems nation-wide.

Read More About Diana

In 1992 Ms. Thomas’ managerial and administrative talents brought her back to Arizona, where she continued to develop and manage multi-million-dollar historic preservation granting funds and projects.

Throughout her career, Ms. Thomas struggled with infertility. Egg donation was cutting edge technology at the time, and Ms. Thomas was told she would have to find her own egg donor, which she did. In 1996, she gave birth to a healthy child, who was one of the first 100 babies born with donor eggs in the US. After that success, infertility doctors contacted her to find egg donors for their other patients. Thus, Ms. Thomas combined her extensive knowledge of the infertility industry, IVF, and donor IVF processes, with her administrative and managerial skills to form one of the first egg donor recruiting/matching agencies in the US: X and Y Consulting. Ms. Thomas grew X and Y Consulting internationally while compiling a donor roster of hundreds of potential egg donors. During this time, she traveled internationally, meeting infertility professionals at every level. Her managerial skills led her to cultivate healthy relationships with industry fertility specialists, business professionals, and vendors, including psychologists, genetic counselors, and laboratories. Thomas’ compassion and experience have helped match thousands of couples with egg donors worldwide.

In 2004 Ms. Thomas, along with Drs. Jeffrey Boldt and James Akin founded Cryo Eggs International (CEI). Dr. Boldt was one of the pioneers in developing egg freezing technology. During this time, a world-renowned medical and scientific advisory board was assembled to support the company’s vision. In 2005, CEI provided the frozen donor oocytes that led to the birth of the first baby in the world born from eggs provided by a commercial egg bank (documented on Good Morning America).

In 2009 Ms. Thomas merged X and Y Consulting (fresh donor cycles) and CEI (egg banking) into The World Egg Bank. As CEO, without any business model precedents, Thomas developed the first independent egg bank. This included all daily operating systems and protocols with a focus on customer relations and service. The key portions of medical and scientific development were managed by Medical Director, Dr. Patricia McShane and Scientific Director, Dr. Kimball Pomeroy. Both are pioneers in their own right and well respected in the infertility community. Ms. Thomas worked with her managerial team to implement quality control, best practices, daily operational functions, and growth opportunities with new technological developments.

In 2021, Ms. Thomas led the company’s expansion into more comprehensive gamete banking services, including donor sperm. The result is the company known today as The World Egg and Sperm Bank. Through Ms. Thomas’ direction, The World Egg and Sperm Bank now offers the best in donor egg and sperm technologies for parents-to-be. The World Egg and Sperm Bank is the only egg and sperm bank in the US that medically manages donors in a single, state-of-the-art facility (Scottsdale, Arizona, USA). Further, we set the global benchmark in providing full, end-to-end logistical control from recruitment to delivery. Our verifiable adherence to international standards and regulation far surpasses US standards.

Patricia M. McShane, M.D.

Director of Clinical Operations

Dr. Pat McShane completed her training in OB/GYN and Reproductive Medicine and Infertility at Brigham and Women’s Hospital in 1983, earning her REI boards in 1985. She completed her Clinical Fellowship at Harvard Medical School. Dr. McShane served as the Assistant Professor of Obstetrics and Gynecology at Harvard and as an Associate Professor at UMass Medical Center.

Read More About Patricia

Coincidentally, after completing her boards in the mid-eighties, the historical beginnings of IVF in the US commenced. Dr. McShane served as the Medical Director of IVF at the Brigham, and soon thereafter at the Reproductive Science Center of New England during the introduction of many key clinical services, including embryo cryopreservation, oocyte donation, and ICSI in the mid-eighties and nineties. Later, she would be involved in the launch of pre-implantation genetic diagnosis and screening and an early trial of oocyte maturation. Dr. McShane was listed as one of Boston’s top doctors. She is one of the first reproductive specialists to bring in-vitro fertilization technology to the US.

From 2007 to 2013, Dr. McShane practiced at the University of Colorado Health Sciences Center where she spearheaded the oocyte vitrification clinical trial, involving immediate thawing and transfer of vitrified oocytes for infertile couples, showing equivalency with fresh oocytes. A current project involves developing CME materials for Oncologists to increase acceptance of fertility preservation options, including oocyte and embryo vitrification. She recently earned a Certificate in Global Public Health at the Colorado School of Public Health.

Dr. McShane has served on the Board of Directors of IntegraMed, a management company for fertility practices, and as the President of the New England Fertility Society. Other memberships include: Offices and Committee Assignments for ASRM, SART Abstract Committee, and Women’s Council.

Dr. McShane is the author of numerous medical reports, reviews, and book chapters, including:

McShane PM, Schiff I. IVF and embryo transfer–what we’ve learned. Contemporary Ob/Gyn 1986;28:125.
McShane PM. “Controlled Ovarian Hyperstimulation for Assisted Reproductive Technologies”: New Horizons in Reproductive Medicine.
Coutifaris C and Mastroianni L (eds). Lancs LA6 2 LA, UK, Parthenon Publishing, 1997: ISBN 1-85-70-793-6.
McShane PM, Danforth A, Carson R. Oocyte donation-an efficient therapy for perimenopausal infertility. Presented at the District ACOG, Meeting New Rhode Island, 1995.
Carson RS, Burgess CM, Glatstein IZ, Singer N, Cunningham DL, McShane PM, Wood DS. Pre-implantation Genetic Diagnosis and The World Egg Bank 9 Cryopreservation of Embryos. Presented at the 532rd ASRM Annual Meeting, Cincinnati, Ohio, 1997.
IVF in women over 42 years old: Is using autologous oocytes a reasonable option? Presented at the 59th ASRM Annual Meeting, San Antonio, TX 2003.
Outcome in women over 35 years of age undergoing consecutive cycles of in vitro fertilization (IVF) using the gonadotropin-releasing hormone antagonist protocol. ASRM Meeting, New Orleans, LA 2006.

Caderina Carrizosa, B.S.

Chief Strategy Officer

Caderina Carrizosa has been using her vision and excellent insight into company management to enhance operations at The World Egg and Sperm Bank for over a decade. She takes the company’s vision and makes it reality through strategy development. She intuitively sees the threads of opportunity that wind through the organization and brings them together into a coherent whole.